Literature DB >> 2459419

Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice.

Z Csapo1, K Brand, R Walther, K Fokas.   

Abstract

Three different human lines of prostate carcinoma were successively transplanted on Balb/c nude mice and the serum values of the prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) were determined simultaneously. In a group of the tumor-bearing animals the influence of endocrine manipulation (castration, estradiol) on the serum concentration of these tumor markers was studied. As far as untreated tumor-bearing mice are concerned, the serum values of both PAP and PSA proved to be strictly dependent on the tumor volume measured. In the exponential growth phase of the grafted tumors, linear growth was linked with a correspondingly increasing PAP and PSA serum level of the test animals. A close correlation was found to exist between the two tumor markers; however, the indicator value of PSA was 20 to 50 times higher than that of PAP under the test conditions. PSA determination yielded no false-negative results, if PAP was elevated. PAP determination was false-negative in 21 per cent of cases with measurable tumors, although the serum level of PSA already showed marked elevation. In treated animals both markers were found to decrease. Arrested growth and tumor regression was associated with falling PAP and PSA serum levels or with levels within normal range. The results of this experimental study support the conclusion that prostate specific antigen represents a substantially more sensitive tumor marker than prostatic acid phosphatase.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459419     DOI: 10.1016/s0022-5347(17)41921-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  Human prostate cancer heterotransplants: a review on this experimental model.

Authors:  Lluis A Lopez-Barcons
Journal:  Asian J Androl       Date:  2010-04-05       Impact factor: 3.285

2.  Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.

Authors:  S R Denmeade; W Lou; J Lövgren; J Malm; H Lilja; J T Isaacs
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

3.  The role of prostatic specific antigen in monitoring prostatic cancer and its prognostic importance.

Authors:  Y Arai; T Yoshiki; K Oishi; H Takeuchi; O Yoshida
Journal:  Urol Res       Date:  1990

Review 4.  Prostate-specific antigen and androgen deprivation therapy.

Authors:  H C Ruckle; J E Oesterling
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

5.  Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.

Authors:  E H Hernes; S D Fosså; S Vaage; P Ogreid; A Heilo; E Paus
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.

Authors:  S D Fosså; H Waehre; E Paus
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

Review 7.  Serially heterotransplanted human prostate tumours as an experimental model.

Authors:  Lluis-A Lopez-Barcons
Journal:  J Cell Mol Med       Date:  2009-10-29       Impact factor: 5.310

8.  A population study of fasting time and serum prostate-specific antigen (PSA) level.

Authors:  Cheryl K Lau; Maggie Guo; Jeannine A Viczko; Christopher T Naugler
Journal:  Asian J Androl       Date:  2014 Sep-Oct       Impact factor: 3.285

Review 9.  Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX.

Authors:  Domenica Rea; Vitale Del Vecchio; Giuseppe Palma; Antonio Barbieri; Michela Falco; Antonio Luciano; Davide De Biase; Sisto Perdonà; Gaetano Facchini; Claudio Arra
Journal:  Biomed Res Int       Date:  2016-05-18       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.